美国TriNetX数据库中葡萄膜炎的发病率、患病率及相关眼部并发症
基于美国TriNetX数据库2013-2023年回顾性横断面与趋势研究,109,026,851名受试者中278,333例(0.26%)诊断为葡萄膜炎,前葡萄膜炎最常见(75.1%)。2013-2023年累积发病率和患病率分别为每10万人212.5例和260.8例,所有亚型发病率及低视力均呈上升趋势。
要点
- 109,026,851名受试者中278,333例(0.26%)患葡萄膜炎,前葡萄膜炎占75.1%。
- 口服泼尼松是最常用免疫抑制剂(22.6%),甲氨蝶呤是最常用保皮质类固醇药物(5.7%)。
- 炎症性脊柱关节病是最常见相关系统性疾病(6.6%),累积发病率和患病率分别为212.5/10万和260.8/10万。
核心结论
- 该研究是美国最大规模葡萄膜炎人群分析之一,显示过去十年数据库中所用葡萄膜炎亚型发病率及患者低视力均上升。
- 作者认为需前瞻性研究识别驱动这些趋势的因素并制定预防视力丧失和眼部并发症的策略。
研究设计与样本
- 回顾性横断面和趋势研究,使用美国TriNetX数据库2013-2023年数据。
- 通过国际疾病分类代码识别葡萄膜炎受试者,并按诊断分为解剖亚型。
主要发现
- 109,026,851名受试者中278,333例(0.26%)诊断为葡萄膜炎,平均年龄56岁(标准差=21,95%CI 55.9-56.1)。
- 女性149,186例(53.6%,95%CI 53.4%-53.8%),白人150,578例(54.1%,95%CI 53.9%-54.3%)。
- 前葡萄膜炎209,073例(75.1%)为最常见亚型。
- 口服泼尼松62,834例(22.6%,95%CI 22.5%-22.8%)为最常用免疫抑制剂,甲氨蝶呤15,817例(5.7%,95%CI 5.6%-5.8%)为最常见保皮质类固醇免疫抑制药。
- 炎症性脊柱关节病18,372例(6.6%,95%CI 6.5%-6.7%)为最常见相关系统性疾病,2013-2023年累积发病率和患病率分别为每10万人212.5例和260.8例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需前瞻性研究识别驱动这些趋势的因素并制定预防视力丧失和眼部并发症的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze the demographics, immunosuppressant use, associated systemic diseases, ocular comorbidities, and incidence and prevalence of uveitis and associated low vision using the United States TriNetX database from 2013-2023. DESIGN: Retrospective cross-sectional and trend study. PARTICIPANTS: Subjects with uveitis in the TriNetX database. METHODS: Subjects with uveitis were identified with International Classification for Disease codes and then divided into anatomic subtypes based on the diagnosis. Incidence and prevalence data were collected from 2013-2023. Additional data collected included demographics, use of systemic immunosuppressive medications, presence of an associated systemic disease, and associated ocular complications. MAIN OUTCOME MEASURES: The primary outcomes were the incidence and prevalence of uveitis (annual and cumulative) with additional analysis by anatomic subtype. Secondary outcomes were the incidence and prevalence of low vision (annual and cumulative). RESULTS: Out of the 109,026,851 subjects in the database, 278,333 (0.26%) had a diagnosis of uveitis. The mean age was 56 years (Standard Deviation = 21, 95% Confidence Interval (CI) 55.9-56.1), and the majority were female (n = 149,186; 53.6%, 95% CI 53.4%-53.8%) and white (n = 150,578; 54.1%, 95% CI 53.9%-54.3%). Anterior uveitis was the most common subtype (n = 209,073, 75.1%). Oral prednisone (n = 62,834; 22.6%, 95% CI 22.5%-22.8%) was the most used immunosuppressant and methotrexate (n = 15,817; 5.7%, 95% CI 5.6%-5.8%) was the most prevalent corticosteroid-sparing immunosuppressive agent. Inflammatory spondyloarthropathies (n = 18,372; 6.6%, 95% CI 6.5%-6.7%) were the most frequently associated systemic disease. The cumulative incidence and prevalence of uveitis from 2013-2023 were 212.5 and 260.8 per 100,000 persons, respectively. CONCLUSIONS: This study represents one of the largest uveitis populations analyzed in the United States, revealing a rising incidence of all uveitis subtypes and an increase in low vision among affected patients over the past decade in the database. Prospective studies are needed to identify the factors driving these trends and to develop strategies to prevent vision loss and ocular complications in uveitis patients.
引用
- Kirupaharan N, Marshall RF, Spangler MD, et al. Incidence and Prevalence of Uveitis and Associated Ocular Complications in the United States TriNetX Database. Am J Ophthalmol. 2025. PMID: 40157445. doi:10.1016/j.ajo.2025.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。